SG11202104205XA - Engineered primate cystine/cysteine degrading enzymes for therapeutic uses - Google Patents

Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Info

Publication number
SG11202104205XA
SG11202104205XA SG11202104205XA SG11202104205XA SG11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA SG 11202104205X A SG11202104205X A SG 11202104205XA
Authority
SG
Singapore
Prior art keywords
therapeutic uses
degrading enzymes
cystine
cysteine degrading
engineered primate
Prior art date
Application number
SG11202104205XA
Inventor
Everett Stone
Wei-Cheng Lu
Christos Karamitros
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202104205XA publication Critical patent/SG11202104205XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y404/00Carbon-sulfur lyases (4.4)
    • C12Y404/01Carbon-sulfur lyases (4.4.1)
    • C12Y404/01001Cystathionine gamma-lyase (4.4.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202104205XA 2018-10-26 2019-10-25 Engineered primate cystine/cysteine degrading enzymes for therapeutic uses SG11202104205XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751197P 2018-10-26 2018-10-26
PCT/US2019/058021 WO2020086937A1 (en) 2018-10-26 2019-10-25 Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Publications (1)

Publication Number Publication Date
SG11202104205XA true SG11202104205XA (en) 2021-05-28

Family

ID=70331739

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104205XA SG11202104205XA (en) 2018-10-26 2019-10-25 Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Country Status (15)

Country Link
US (1) US20210380962A1 (en)
EP (1) EP3870081A4 (en)
JP (1) JP2022505689A (en)
KR (1) KR20210084539A (en)
CN (1) CN113260324A (en)
AR (1) AR116866A1 (en)
AU (1) AU2019363606A1 (en)
BR (1) BR112021007687A2 (en)
CA (1) CA3117046A1 (en)
CO (1) CO2021006432A2 (en)
IL (1) IL282626A (en)
MX (1) MX2021004754A (en)
SG (1) SG11202104205XA (en)
TW (1) TW202029967A (en)
WO (1) WO2020086937A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275279A1 (en) * 2005-06-06 2006-12-07 Rozzell J D Methods for dissolving cystine stones and reducing cystine in urine
AU2011212885B2 (en) * 2010-02-04 2015-10-01 Aemase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
AU2014312168B2 (en) * 2013-08-29 2020-08-06 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
CA2922550C (en) * 2013-08-29 2022-12-06 Board Of Regents, The University Of Texas System Engineered primate l-methioninase for therapeutic purposes
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
WO2018209211A1 (en) * 2017-05-12 2018-11-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Also Published As

Publication number Publication date
EP3870081A4 (en) 2023-01-18
CA3117046A1 (en) 2020-04-30
TW202029967A (en) 2020-08-16
AR116866A1 (en) 2021-06-23
WO2020086937A1 (en) 2020-04-30
IL282626A (en) 2021-06-30
BR112021007687A2 (en) 2021-08-10
MX2021004754A (en) 2021-06-08
US20210380962A1 (en) 2021-12-09
JP2022505689A (en) 2022-01-14
CO2021006432A2 (en) 2021-06-10
EP3870081A1 (en) 2021-09-01
KR20210084539A (en) 2021-07-07
CN113260324A (en) 2021-08-13
AU2019363606A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
IL244263B (en) Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
IL282092B (en) Engineered enzymes
EP3490987A4 (en) Novel therapeutic agents for the treatment of hbv infection
EP3576765A4 (en) Targeted engineered interferon and uses thereof
EP4073232A4 (en) Organoid cultures
IL275482A (en) Esketamine for the treatment of depression
IL261856B (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP3705545A4 (en) Surface treatment composition
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
IL279880A (en) Engineered phosphopentomutase variant enzymes
EP3445179A4 (en) Cannabis-enriched enzymatically treated therapeutic composition
EP3481425A4 (en) Human-enzyme mediated depletion of cystine for treating patients with cystinuria
IL285634A (en) Novel uses of botulinum neurotoxin for the treatment of tremor
IL288937A (en) Improved treatment using eyp001
GEP201706673B (en) Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate
GB201916237D0 (en) Novel treatment
EP3880885A4 (en) Surface treatment composition
GB202007431D0 (en) Cysteine protease
IL282626A (en) Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
EP3722867A4 (en) Soft contact lens treatment solution
EP3679046A4 (en) Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
EP3684309A4 (en) Devices and methods for reducing cystine crystalsin vivo
EP3573609A4 (en) Use of senicapoc for treatment of stroke
IL286000A (en) Esketamine for the treatment of depression
EP3576750A4 (en) Idoxuridine and its analogs as neuroprotectans for the treatment of parkinsonism